221 related articles for article (PubMed ID: 25880014)
1. Diffusion-weighted MRI for imaging cell death after cytotoxic or apoptosis-inducing therapy.
Papaevangelou E; Almeida GS; Jamin Y; Robinson SP; deSouza NM
Br J Cancer; 2015 Apr; 112(9):1471-9. PubMed ID: 25880014
[TBL] [Abstract][Full Text] [Related]
2. Acute tumour response to the MEK1/2 inhibitor selumetinib (AZD6244, ARRY-142886) evaluated by non-invasive diffusion-weighted MRI.
Beloueche-Babari M; Jamin Y; Arunan V; Walker-Samuel S; Revill M; Smith PD; Halliday J; Waterton JC; Barjat H; Workman P; Leach MO; Robinson SP
Br J Cancer; 2013 Sep; 109(6):1562-9. PubMed ID: 23942066
[TBL] [Abstract][Full Text] [Related]
3. Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib.
Bocci G; Falcone A; Fioravanti A; Orlandi P; Di Paolo A; Fanelli G; Viacava P; Naccarato AG; Kerbel RS; Danesi R; Del Tacca M; Allegrini G
Br J Cancer; 2008 May; 98(10):1619-29. PubMed ID: 18443598
[TBL] [Abstract][Full Text] [Related]
4. Combination effects of SMAC mimetic birinapant with TNFα, TRAIL, and docetaxel in preclinical models of HNSCC.
Eytan DF; Snow GE; Carlson SG; Schiltz S; Chen Z; Van Waes C
Laryngoscope; 2015 Mar; 125(3):E118-24. PubMed ID: 25431358
[TBL] [Abstract][Full Text] [Related]
5. SMAC mimetic birinapant inhibits hepatocellular carcinoma growth by activating the cIAP1/TRAF3 signaling pathway.
Ding J; Qin D; Zhang Y; Li Q; Li Y; Li J
Mol Med Rep; 2020 Mar; 21(3):1251-1257. PubMed ID: 31922244
[TBL] [Abstract][Full Text] [Related]
6. Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts.
Prewett MC; Hooper AT; Bassi R; Ellis LM; Waksal HW; Hicklin DJ
Clin Cancer Res; 2002 May; 8(5):994-1003. PubMed ID: 12006511
[TBL] [Abstract][Full Text] [Related]
7. Correlation of Ultrasound Shear Wave Elastography with Pathological Analysis in a Xenografic Tumour Model.
Elyas E; Papaevangelou E; Alles EJ; Erler JT; Cox TR; Robinson SP; Bamber JC
Sci Rep; 2017 Mar; 7(1):165. PubMed ID: 28279018
[TBL] [Abstract][Full Text] [Related]
8. Differentiated human colorectal cancer cells protect tumor-initiating cells from irinotecan.
Emmink BL; Van Houdt WJ; Vries RG; Hoogwater FJ; Govaert KM; Verheem A; Nijkamp MW; Steller EJ; Jimenez CR; Clevers H; Borel Rinkes IH; Kranenburg O
Gastroenterology; 2011 Jul; 141(1):269-78. PubMed ID: 21459094
[TBL] [Abstract][Full Text] [Related]
9. Patient-derived glioblastoma cells show significant heterogeneity in treatment responses to the inhibitor-of-apoptosis-protein antagonist birinapant.
Zakaria Z; Tivnan A; Flanagan L; Murray DW; Salvucci M; Stringer BW; Day BW; Boyd AW; Kögel D; Rehm M; O'Brien DF; Byrne AT; Prehn JH
Br J Cancer; 2016 Jan; 114(2):188-98. PubMed ID: 26657652
[TBL] [Abstract][Full Text] [Related]
10. Preclinical study of treatment response in HCT-116 cells and xenografts with (1) H-decoupled (31) P MRS.
Darpolor MM; Kennealey PT; Le HC; Zakian KL; Ackerstaff E; Rizwan A; Chen JH; Sambol EB; Schwartz GK; Singer S; Koutcher JA
NMR Biomed; 2011 Nov; 24(9):1159-68. PubMed ID: 21994185
[TBL] [Abstract][Full Text] [Related]
11. Equivalent effect of DNA damage-induced apoptotic cell death or long-term cell cycle arrest on colon carcinoma cell proliferation and tumour growth.
Bhonde MR; Hanski ML; Notter M; Gillissen BF; Daniel PT; Zeitz M; Hanski C
Oncogene; 2006 Jan; 25(2):165-75. PubMed ID: 16170360
[TBL] [Abstract][Full Text] [Related]
12. The histone deacetylase inhibitor PXD101 increases the efficacy of irinotecan in in vitro and in vivo colon cancer models.
Na YS; Jung KA; Kim SM; Hong YS; Ryu MH; Jang SJ; Moon DH; Cho DH; Kim JC; Lee JS; Kim TW
Cancer Chemother Pharmacol; 2011 Aug; 68(2):389-98. PubMed ID: 21046105
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic mechanisms of irinotecan sensitivity in colorectal cancer cell lines.
Crea F; Giovannetti E; Cortesi F; Mey V; Nannizzi S; Gallegos Ruiz MI; Ricciardi S; Del Tacca M; Peters GJ; Danesi R
Mol Cancer Ther; 2009 Jul; 8(7):1964-73. PubMed ID: 19531575
[TBL] [Abstract][Full Text] [Related]
14. The novel SMAC mimetic birinapant exhibits potent activity against human melanoma cells.
Krepler C; Chunduru SK; Halloran MB; He X; Xiao M; Vultur A; Villanueva J; Mitsuuchi Y; Neiman EM; Benetatos C; Nathanson KL; Amaravadi RK; Pehamberger H; McKinlay M; Herlyn M
Clin Cancer Res; 2013 Apr; 19(7):1784-94. PubMed ID: 23403634
[TBL] [Abstract][Full Text] [Related]
15. Diffusion weighted magnetic resonance imaging (DW-MRI) as a non-invasive, tissue cellularity marker to monitor cancer treatment response.
Fliedner FP; Engel TB; El-Ali HH; Hansen AE; Kjaer A
BMC Cancer; 2020 Feb; 20(1):134. PubMed ID: 32075610
[TBL] [Abstract][Full Text] [Related]
16. Treatment of human colon cancer xenografts with TRA-8 anti-death receptor 5 antibody alone or in combination with CPT-11.
Oliver PG; LoBuglio AF; Zinn KR; Kim H; Nan L; Zhou T; Wang W; Buchsbaum DJ
Clin Cancer Res; 2008 Apr; 14(7):2180-9. PubMed ID: 18381960
[TBL] [Abstract][Full Text] [Related]
17. Intravoxel incoherent motion diffusion-weighted imaging for monitoring chemotherapeutic efficacy in gastric cancer.
Song XL; Kang HK; Jeong GW; Ahn KY; Jeong YY; Kang YJ; Cho HJ; Moon CM
World J Gastroenterol; 2016 Jun; 22(24):5520-31. PubMed ID: 27350730
[TBL] [Abstract][Full Text] [Related]
18. Effects of quercetin combined with anticancer drugs on metastasis-associated factors of gastric cancer cells: in vitro and in vivo studies.
Lei CS; Hou YC; Pai MH; Lin MT; Yeh SL
J Nutr Biochem; 2018 Jan; 51():105-113. PubMed ID: 29125991
[TBL] [Abstract][Full Text] [Related]
19. IAP antagonists Birinapant and AT-406 efficiently synergise with either TRAIL, BRAF, or BCL-2 inhibitors to sensitise BRAFV600E colorectal tumour cells to apoptosis.
Perimenis P; Galaris A; Voulgari A; Prassa M; Pintzas A
BMC Cancer; 2016 Aug; 16():624. PubMed ID: 27520705
[TBL] [Abstract][Full Text] [Related]
20. Elimination of hepatic metastases of colon cancer cells via p53-independent cross-talk between irinotecan and Apo2 ligand/TRAIL.
Ravi R; Jain AJ; Schulick RD; Pham V; Prouser TS; Allen H; Mayer EG; Yu H; Pardoll DM; Ashkenazi A; Bedi A
Cancer Res; 2004 Dec; 64(24):9105-14. PubMed ID: 15604280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
